These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29182807)

  • 1. [Application of Liquid Biopsy for Lung Cancer Treatment.].
    Mori S; Yatabe Y
    Rinsho Byori; 2016 May; 64(4):407-411. PubMed ID: 29182807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy tracking of lung tumor evolutions over time.
    Russo A; De Miguel Perez D; Gunasekaran M; Scilla K; Lapidus R; Cooper B; Mehra R; Adamo V; Malapelle U; Rolfo C
    Expert Rev Mol Diagn; 2019 Dec; 19(12):1099-1108. PubMed ID: 31608732
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
    Bennett CW; Berchem G; Kim YJ; El-Khoury V
    Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Biopsy in Tumor Genetic Diagnosis.
    Jung A; Kirchner T
    Dtsch Arztebl Int; 2018 Mar; 115(10):169-174. PubMed ID: 29587961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
    Goto K; Ichinose Y; Ohe Y; Yamamoto N; Negoro S; Nishio K; Itoh Y; Jiang H; Duffield E; McCormack R; Saijo N; Mok T; Fukuoka M
    J Thorac Oncol; 2012 Jan; 7(1):115-21. PubMed ID: 21900837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
    Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
    Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
    Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
    Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible applications of circulating tumor cells in patients with non small cell lung cancer.
    Tartarone A; Rossi E; Lerose R; Mambella G; Calderone G; Zamarchi R; Aieta M
    Lung Cancer; 2017 May; 107():59-64. PubMed ID: 27339469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
    Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.
    Isobe K; Hata Y; Kobayashi K; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Takagi K; Homma S
    Anticancer Res; 2012 Aug; 32(8):3339-44. PubMed ID: 22843912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure.
    Lee H; Jeon S; Seo JS; Goh SH; Han JY; Cho Y
    Biomaterials; 2016 Sep; 101():251-7. PubMed ID: 27294542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Size distribution of cell-free DNA in oncology.
    Udomruk S; Orrapin S; Pruksakorn D; Chaiyawat P
    Crit Rev Oncol Hematol; 2021 Oct; 166():103455. PubMed ID: 34464717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.